In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Start-Up Previews (07/2010)

Executive Summary

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Alzheimer's Start-Ups Face A Discovery And Clinical Crossroads," features profiles of AlzProtect, Axerion Therapeutics, Cognition Therapeutics and Galantos Pharma. "The Future of Laparoscopy: Single Incision, NOTES And Robots," features profiles of EndoControl, Ovesco Endoscopy, SurgiQuest and Virtual Incision. Plus these Start-Ups Across Health Care: Antabio, Beta-Stim, CMP Therapeutics, Elixir Medical, Kerecis, Optivia Biotechnology, Quanterix and reinnervate.

You may also be interested in...



Virtual Incision Corp.

The debate surrounding the future of minimally invasive surgery -- whether single-incision laparoscopy will prevail, or whether it is merely a stepping stone to a world of incisionless NOTES procedures - is not really relevant to Virtual Incision, a start-up developing mini surgical robots. The company's founders believe that in vivo robots will free a surgeon of any constraints due to the method of entering the body.

Ovesco Endoscopy AG

With technology licensed from the University of Tuebingen, Ovesco Endoscopy has set out to address one of the biggest challenges of NOTES procedures: achieving closure of the gastric wall while working through a flexible endoscope. Ovesco has developed a clipping system that imitates the mechanics - the geometry and force pattern - of a surgical suture, but with advantages.

Kerecis Ltd.

The Marigen Lipid Enhanced Matrix from Kerecis Ltd. is derived from fish skin and has been shown to effectively improve the healing of wounds and surgical cuts. The company says that Marigen offers significant advantages over existing human and porcine-derived products, including improved manufacturing economics, lower risk of disease transfer and the promise of better clinical outcomes.

Related Content

Related Companies

UsernamePublicRestriction

Register

IV003534

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel